Mesh Augmented Reinforcement of Abdominal Wall Suture Line to Limit the Rate of Incisional Hernia Occurrence

NCT ID: NCT05424484

Last Updated: 2025-11-19

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 123 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-11-22
• Study Completion Date: 2028-09-30

Brief Summary

The purpose of this prospective, pivotal, multi-center, single-arm, pre-market, investigational clinical study is to assess the safety and performance of Deternia™ Self-Gripping Resorbable Mesh when used for suture line reinforcement after midline laparotomy in clean and clean-contaminated fields (CDC Classification I and II). Data from this study will be used to support market applications. The indication under investigation is reinforcement of midline laparotomy to limit the rate of incisional hernia (IH) in clean and clean-contaminated surgeries (CDC Classification I and II).

Detailed Description

The primary objective of this investigation is to evaluate the performance of Deternia™ Self-Gripping Resorbable Mesh when used for suture line reinforcement after elective midline laparotomy in clean and clean-contaminated fields (CDC Classification I and II) at 12 months post-operatively and to demonstrate expected performance in terms of rate of IH occurrence relative to a performance goal (based on historical data on primary laparotomy incision suture closure with small bites only).

The secondary objectives are to evaluate the safety and performance of Deternia™ Self-Gripping Resorbable Mesh when used for suture line reinforcement after elective midline laparotomy in clean and clean contaminated fields (CDC Classification I and II) within 36 months postoperatively.

Conditions

Incisional Hernia; Incisional Hernia of Midline of Abdomen; Midline Laparotomy

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

Hernia prevention cohort

single arm study, no control arm

Group Type: EXPERIMENTAL

Self-Gripping Resorbable Mesh

Intervention Type: DEVICE

Self-Gripping Resorbable Mesh used for suture line reinforcement after midline laparotomy in clean and clean-contaminated fields (CDC Classification I and II).

Interventions

Self-Gripping Resorbable Mesh

Self-Gripping Resorbable Mesh used for suture line reinforcement after midline laparotomy in clean and clean-contaminated fields (CDC Classification I and II).

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Subject has provided informed consent.

2. Subject is ≥18 years of age at the time of consent.

3. Subject will be undergoing an elective surgery with a planned/possible midline laparotomy with retrorectus mesh placement.

3a. Subject will be undergoing an elective laparoscopy with a planned possibility of a conversion to midline laparotomy or an elective laparoscopy with a planned possible midline laparotomy for specimen extraction.

Exclusion Criteria

1. Subject is undergoing emergency surgery, i.e. lifesaving procedures performed where patient is in imminent danger of death

2. Subject has a history of allergic reactions after application of poly-L-lactide, poly-trimethylene carbonate copolymers (PLLA/TMC)

3. Subject is pregnant or is planning pregnancy during study duration period (Females of child-bearing potential will be required to provide either a urine or serum pregnancy test (except for subjects who are surgically sterile or are at least 2 years postmenopausal)) 3a. Subject is breastfeeding or is planning to breastfeed during the study duration period

4. Subject is unable or unwilling to comply with the study requirements or follow-up schedule

5. Subject is scheduled for another planned surgery, and subsequent surgery would jeopardize previous application of study treatment

6. Subject with a body mass index (BMI) > 45 kg/m2

7. Subjects with the following medical interventions/medical conditions are excluded from participation in the study: uncontrolled diabetes (hemoglobin A1c (Hb1Ac) > 60mmol/mol), cirrhosis, stoma wearers

8. Concomitant ostomy (stoma creation or closure)

9. Subject who had received a mesh in a previous ventral hernia repair or has an existing ventral hernia > 2 cm

10. Subject with a life expectancy inferior to the study follow-up duration (36 months)

11. Study procedure is a relaparotomy within 30 days of previous abdominal surgery

12. Subject with an American Society of Anesthesiologists (ASA) scores higher than 3

13. Subject has participated in an investigational drug study within the washout period of the drug or in a device study that would interfere with mesh implantation or assessment of Incisional Hernia

14. Subject with current chemo and/or radiation therapy within 2 weeks of procedure

Only exclusion of chemotherapeutic drugs that have:

• Cytotoxic effect and/or
• Inhibit of cell replication and/or
• Impaired tissue healing

15. Subject with any history of ascites

16. Subject has a medical condition that precludes the patient from participation in the opinion of the investigator

17. Subject is undergoing a vascular procedure other than abdominal aortic aneurysm (AAA) surgery (i.e, only AAA surgeries accepted)

1. Subject's study procedure is in a contaminated or infected site as assessed by the Investigator(s) (CDC Class 3 and 4)

2. Abdomen is left open at the end of the procedure

3. Subject has an unsuspected ventral hernia >2cm encountered at the time of laparotomy

4. Inability to close the anterior fascia or keep the mesh securely out of the peritoneal cavity

5. Second-look procedure planned

6. Cases requiring a full-thickness partial resection of the abdominal wall (in particular the midline) because of involvement in neoplastic process or complex fistula

7. Inoperable tumor/poor prognostic cancer/patient non curatively treated

8. Subject has a suture length to wound length ratio< 3.5/1

9. Subject has any ongoing infection at the time of the surgery, that is uncontrolled and/or requiring treatment such as antibiotics

10. Subject was not implanted with Deternia™ Self Gripping Resorbable Mesh

11. Subject requires more than 1 mesh

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medtronic - MITG

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Elisa Mäkäräinen, MD

Role: STUDY_CHAIR

Oululu University Hospital, Oululu, Finland

Locations

Clinical Hospital Center Sisters of Mercy

Zagreb, , Croatia

University Hospital Center of Zagreb

Zagreb, , Croatia

Klinikum Braunschweig

Braunschweig, , Germany

Pius-Hospital Medical Campus University of Oldenburg

Oldenburg, , Germany

Barmherzige Brüder Regensburg

Regensburg, , Germany

IJsselland Ziekenhuis

Capelle aan den IJssel, , Netherlands

Maastricht University Medical Center

Maastricht, , Netherlands

Consorci Sanitari de l'Anoia Hospital Universitari d'Igualada

Igualada, Barcelona, Spain

Hospital de la Santa Creu i Sant Pau

Barcelona, , Spain

Hospital Universitario Ramón y Cajal

Madrid, , Spain

Hospital Universitario Virgen Macarena

Seville, , Spain

Countess Of Chester Hospital NHS Foundation Trust

Chester, Cheshire, United Kingdom

Cardiff and Vale University Local Health Board

Cardiff, , United Kingdom

Countries

Croatia; Germany; Netherlands; Spain; United Kingdom

Other Identifiers

CIV-22-05-039590

Identifier Type: OTHER

Identifier Source: secondary_id

MDT20049MARS

Identifier Type: -

Identifier Source: org_study_id